Publication:
Interaction between warfarin and astaxanthin: A case report

dc.contributor.authorSantiyanon N.
dc.contributor.authorYeephu S.
dc.date.accessioned2021-04-05T03:03:17Z
dc.date.available2021-04-05T03:03:17Z
dc.date.issued2019
dc.date.issuedBE2562
dc.description.abstractThis report explains the potential interaction between warfarin and astaxanthin in a 69-year-old Thai woman with history of ischemic stroke. Before taking astaxanthin, the patient used constant doses of warfarin, atenolol, digoxin, aspirin, omeprazole, and simvastatin concomitantly for 17 days without any signs and symptoms of adverse events. One day after astaxanthin was supplemented to her treatment regimen, ecchymosis was found on the right side of her groin and thigh. On the next day, area of ecchymosis was larger. International normalized ratio (INR) values increased from 1.4 to 10.38. Warfarin and astaxanthin were withheld and vitamin K was given. Two days later, INR reduced to 1.43 and symptoms of ecchymosis were better. Causality assessment of adverse drug reaction indicated a probable relationship between bleeding symptoms and astaxanthin supplementation. Counseling the patients and caregivers as well as monitoring for potential interactions with dietary supplements should be considered as an active process in order to prevent negative outcomes to patients undergoing warfarin therapy. <Learning objective: Astaxanthin, a powerful antioxidant, has been claimed to have benefits on the cardiovascular system. The populations with high risk of atherosclerotic diseases, including patients treated with warfarin may take astaxanthin for improving their disease and overall health status. Interestingly, warfarin displays clinically significant interactions with various dietary supplements and may have potential to develop unwanted anticoagulation effects when used concomitantly with astaxanthin.> © 2019 Japanese College of Cardiology
dc.format.mimetypeapplication/pdf
dc.identifier.citationJournal of Cardiology Cases. Vol 19, No.5 (2019), p.173-175
dc.identifier.doi10.1016/j.jccase.2019.01.002
dc.identifier.issn18785409
dc.identifier.other2-s2.0-85061640112
dc.identifier.urihttps://hdl.handle.net/20.500.14740/5350
dc.rights.holderScopus
dc.subject.otherAcetylsalicylic acid
dc.subject.otherAmiodarone
dc.subject.otherAmlodipine
dc.subject.otherAstaxanthin
dc.subject.otherAtenolol
dc.subject.otherDigoxin
dc.subject.otherOmeprazole
dc.subject.otherSimvastatin
dc.subject.otherVitamin K group
dc.subject.otherWarfarin
dc.subject.otherActivated partial thromboplastin time
dc.subject.otherAdult
dc.subject.otherArm ecchymosis
dc.subject.otherArticle
dc.subject.otherBedtime dosage
dc.subject.otherBrain ischemia
dc.subject.otherCase report
dc.subject.otherClinical article
dc.subject.otherDrug dose reduction
dc.subject.otherDrug potentiation
dc.subject.otherDysarthria
dc.subject.otherEcchymosis
dc.subject.otherElectrocardiography
dc.subject.otherEssential hypertension
dc.subject.otherEvening dosage
dc.subject.otherFemale
dc.subject.otherHemiparesis
dc.subject.otherHuman
dc.subject.otherInguinal region ecchymosis
dc.subject.otherInternational normalized ratio
dc.subject.otherMicrocapsule
dc.subject.otherMiddle aged
dc.subject.otherMorning dosage
dc.subject.otherPersistent atrial fibrillation
dc.subject.otherPriority journal
dc.subject.otherRange of motion
dc.subject.otherSwelling
dc.subject.otherThigh ecchymosis
dc.titleInteraction between warfarin and astaxanthin: A case report
dc.typeArticle
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85061640112&doi=10.1016%2fj.jccase.2019.01.002&partnerID=40&md5=6a7366da4ac499d8657b5effd013806b

Files